ArticleCancer immunology, immunotherapy : CII2022

Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study.

Kaili Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.